ISSAQUAH, Wash., Dec 1 2020 / PRNewswire / – CaaMTech, Inc., today announced that the company has entered into a collaborative research agreement with the Leibniz Institute for Natural Products Research and Infection Biology to research psychedelic mushroom compositions. The Leibniz Institute for Natural Products and Infection Biology Research (also known as the Hans Knöll Institute [HKI] after its founder) is located in Jena, Germany. Famous mycologist Teacher. Dr. Dirk Hoffmeister, head of the pharmaceutical microbiology research group, will lead the research on behalf of HKI.
The collaborative research aims to fill several gaps in the scientific understanding of the chemical composition of psychedelic mushrooms containing psilocybin, colloquially known as “magic mushrooms”. Magic mushrooms (and their most well-known psychedelic compound, psilocybin) have been the subject of a wave of new research in recent years. More recently, magic mushrooms have been decriminalized in several US jurisdictions and Oregon voters overwhelmingly decided to legalize psychotherapy using these mushrooms in a November vote measure.
“Psilocybin is only one of the many tryptamines found in magic mushrooms and probably not the one that has the most potential or the strongest effects,” said Dr. Andrew Chadayne, CEO of CaaMTech. “Understanding the chemical makeup of magic mushrooms allows us to quantitatively distinguish their effects from pure psilocybin and harness its benefits. “
The research, being conducted by Dr. Hoffmeister’s team at HKI, will examine, among other things, chemical variability within and between strains of magic mushrooms.
“The metabolic profiling of these fungi is an exciting endeavor,” said Dr. Hoffmeister. “A more comprehensive view of their metabolic diversity has not yet been undertaken, but it is needed to help us better understand their effects. From an academic point of view, it can also tell us why nature evolved these compounds. “
CaaMTech is the leading drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech improves the health and happiness of humanity by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.
SOURCE CaaMTech, Inc.